semaglutide

Telehealth Weight Loss Market Worth $6.9 Billion And Growing

April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their […]

Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs

News / John LaRosa

March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated

U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »

Weight Watchers Reports Q4 and 2023 Results

News / John LaRosa

Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year

Weight Watchers Reports Q4 and 2023 Results Read More »

Medifast Reports Q4 and Full Year 2023 Results

News / John LaRosa

Feb. 20, 2024 Medifast reported full-year and Q4 results on February 20, 2023. 2023 revenues came in at $1.07 billion. The company employed 41,100 active earning Optavia health coaches, who had quarterly earnings of $4,648 (or $18,592 on an annual rate). Management said that: “We are realigning our business to respond to the evolving dynamics

Medifast Reports Q4 and Full Year 2023 Results Read More »

More Obesity Drugs In The Pipeline

Uncategorized / John LaRosa

January 20, 2024 Novo Nordisk and Eli Lilly aren’t the only drug companies active in the prescription diet drugs space. Viking Therapeutics has a dual GLP-1/GIP agonist in Phase 2 clinical trials for treating obesity and liver fat reduction for injectable and oral administration. Rhythm Pharmaceuticals has an FDA-approved treatment for the treatment of MC4R-pathway-related

More Obesity Drugs In The Pipeline Read More »

Eli Lilly Offers Weight Loss Drug Direct to Consumers

News / John LaRosa

January 5, 2023 Eli Lilly and Company launched a website, lillydirect.com, to enable people to directly order from the drug maker including its weight-loss medicine Zepbound as well as connect people with obesity and other conditions with telehealth companies. The service, called LillyDirect, comes on the back on extraordinary demand seen over the last year

Eli Lilly Offers Weight Loss Drug Direct to Consumers Read More »

Semaglutide Boom – The Beginning of a Decline? New FDA Report

News / John LaRosa

January 4, 2024 The history of weight loss drugs in the U.S. is filled with meds that were taken off the market due to nasty side effects, going back to the phen/fen crisis of 1997. Many more followed (Belviq, Qsymia, Taranabant, Acomplia) . These side effects did not emerge until years after entering the market

Semaglutide Boom – The Beginning of a Decline? New FDA Report Read More »

Medifast Enters Medical Weight Loss Market

News / John LaRosa

Dec. 14, 2023 Medifast on Wednesday marked its first entry into the medically supported weight loss market through a collaboration with LifeMD Inc., a provider of virtual primary care. This venture brings together Optavia’s personalized, coach-guided approach with medical expertise from board-certified LifeMD clinicians and access to weight loss medications, including GLP-1s. Medifast has committed

Medifast Enters Medical Weight Loss Market Read More »

Weight Watchers Reports 3rd Quarter Results

News / John LaRosa

November 2, 2023 WW reported results for its 3rd quarter. Management reported that: “We have successfully returned WeightWatchers to subscriber growth, with Q3 end of period subscribers up 6% year-over-year to 4.0 million. This is a significant achievement and a direct result of our work in reinvigorating our core product,” said Sima Sistani, the company’s

Weight Watchers Reports 3rd Quarter Results Read More »

Obesity Drug Sales Continue To Soar

News / John LaRosa

Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In

Obesity Drug Sales Continue To Soar Read More »

(813) 971-8080